Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2018 · 10-Q
Revenue$99.54M$99.54M+31.3% vs Q2 2017 Net Income$30.74M$30.74M+77.0% vs Q2 2017 EPS Diluted$0.57$0.57+78.1% vs Q2 2017 Operating Income$35,720,000+37.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$6,252,000−75.4% Margins · derivedOperating margin35.9%+1.5 pt vs Q2 2017
Net margin30.9%+8.0 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end